Actavis’ Investment Venture To Acquire Stake In Techpool Bio-Pharma
This article was originally published in PharmAsia News
Executive Summary
Investor firm Smart Nice, majority-owned by pharmaceutical company Actavis, will accept 20 million shares of Techpool Bio-Pharma from Guangzhou Bopu and buy another 20 million shares at 5 yuan per share. Shanghai Industrial Pharmaceutical Investment and its subsidiary Huarui Investments will decrease their equity in Techpool from 51 percent to 40.8 percent, while Smart Nice will become a strategic investor with 40 percent stake. According to sources, both companies have signed an MOU to collaborate in the areas of medical science, technology, business operation and pharmaceutical-related fields. (Click here for more - Chinese language)